Kallyope’s focus on the gut-brain axis yields a diverse portfolio

New York City-based Kallyope is one of the few biotechs focused solely on the gut-brain axis. 

The privately-held company has built a cross-disciplinary team that weaves together advanced technologies in sequencing, bioinformatics, neural imaging, human genetics, and cellular and molecular biology. 

The company has raised $479 million to date, including a $236 million Series D financing in February.

Jay Galeota

The president and CEO of the company is Jay Galeota, who worked at Merck & Co. (NYSE:MRK) for almost three decades.  

“I was fortunate enough to lead the team that brought Merck into diabetes with Januvia (sitagliptin) and Janumet (sitagliptin/metformin),” Galeota said. Last year, the drugs generated $5.3 billion in revenue.

The discoverers of sitagliptin, Nancy Thornberry and Ann Weber, are both Merck alumni who are now senior executives at Kallyope. Thornb…

Read more
  • 0